Document and Entity Information
Document and Entity Information | 3 Months Ended |
Jul. 31, 2017shares | |
Document And Entity Information | |
Entity Registrant Name | BIOSYNERGY INC |
Entity Central Index Key | 715,812 |
Document Type | 10-Q |
Document Period End Date | Jul. 31, 2017 |
Amendment Flag | false |
Current Fiscal Year End Date | --04-30 |
Is Entity a Well-known Seasoned Issuer? | No |
Is Entity a Voluntary Filer? | No |
Is Entity's Reporting Status Current? | No |
Entity Filer Category | Smaller Reporting Company |
Entity Common Stock, Shares Outstanding | 14,935,511 |
Document Fiscal Period Focus | Q1 |
Document Fiscal Year Focus | 2,018 |
Balance Sheets (Unaudited)
Balance Sheets (Unaudited) - USD ($) | Jul. 31, 2017 | Apr. 30, 2017 |
Current assets | ||
Cash | $ 1,112,460 | $ 1,040,582 |
Accounts receivable, trade (Net of allowance for doubtful accounts of $500 at July 31, 2016 and April 30, 2016) | 213,281 | 267,545 |
Inventories | 155,471 | 186,312 |
Prepaid expenses | 35,749 | 32,165 |
Total current assets | 1,516,961 | 1,526,604 |
Equipment and leasehold improvements | ||
Equipment | 201,764 | 201,764 |
Leasehold improvements | 23,447 | 23,447 |
[PropertyPlantAndEquipmentGross] | 225,211 | 225,211 |
Less accumulated depreciation and amortization | (207,905) | (205,326) |
Total equipment and leasehold improvements, net | 17,306 | 19,885 |
Other assets | ||
Patents less accumulated amortization | 68,201 | 70,372 |
Pending patents | 69,420 | 69,420 |
Deposits | 5,937 | 5,937 |
Total other assets | 143,558 | 145,729 |
[Assets] | 1,677,825 | 1,692,218 |
Current Liabilities | ||
Accounts payable | 21,034 | 3,842 |
Accrued compensation and payroll taxes | 14,149 | 42,472 |
Other accrued liabilities | 1,931 | 3,589 |
Accrued vacation | 27,351 | 21,795 |
Total current liabilities | 64,465 | 71,698 |
Deferred income taxes | 34,800 | 34,800 |
Shareholders equity | ||
Common stock, no par value: 20,000,000 authorized shares issued: 14,935,511 shares outstanding at July 31, 2016 and April 30, 2016 | 660,988 | 660,988 |
Receivable from Affiliate | (19,699) | (19,699) |
Retained earnings | 937,271 | 944,431 |
Total Shareholders Equity | 1,578,560 | 1,585,720 |
[LiabilitiesAndStockholdersEquity] | $ 1,677,825 | $ 1,692,218 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - USD ($) | Jul. 31, 2017 | Apr. 30, 2017 |
Balance Sheets | ||
Net of allowance for doubtful accounts | $ 500 | $ 500 |
Common stock, no par value | 20,000,000 | 20,000,000 |
Authorized shares issued and outstanding | 14,935,511 | 14,935,511 |
Statements of Operations (Unaud
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Income Statement [Abstract] | ||
Net Sales | $ 302,904 | $ 290,047 |
Cost of Sales | 98,236 | 91,231 |
Gross Profit | 204,668 | 198,816 |
Operating Expenses | ||
Marketing | 45,574 | 47,721 |
General and administrative | 129,443 | 127,002 |
Research and development | 40,667 | 42,197 |
Total Operating Expenses | 215,684 | 216,920 |
Loss Income from Operations | (11,016) | (18,104) |
Other Income | ||
Interest income | 108 | 107 |
Other income | 480 | 480 |
Total Other Income | 588 | 587 |
Net income (loss) before income taxes | (10,428) | (17,517) |
Provision (benefit) for income taxes | (3,268) | (5,474) |
Net Loss | $ (7,160) | $ (12,043) |
Net income per common share-basic and diluted | $ (.0005) | $ (.001) |
Weighted-Average common stock outstanding-basic and diluted | 14,935,511 | 14,935,511 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Cash flows from operating activities | ||
Net income | $ (7,160) | $ (12,043) |
Adjustments to reconcile net loss to cash provided by (used in) operating activities | ||
Depreciation and amortization | 4,750 | 4,270 |
Changes in assets and liabilities | ||
Accounts receivable | 54,264 | 61,173 |
Inventories | 30,841 | (18,179) |
Prepaid expenses and other | (3,584) | (9,455) |
Accounts payable and accrued expenses | (7,233) | 14,844 |
Total Adjustments | 79,038 | 52,653 |
Net cash (used in) provided by operating activities | 71,878 | 40,610 |
Cash flows from investing activities | ||
Patents and patents pending | 0 | 0 |
Purchase of equipment | 0 | (3,312) |
Net cash used in investing activities | 0 | (3,312) |
Increase (decrease) in cash and cash equivalents | 71,878 | 37,298 |
Cash Beginning Period | 1,040,582 | 1,091,649 |
Cash Ending Period | 1,112,460 | 1,128,947 |
Supplemental Cash Flow Information | ||
Interest paid | 0 | |
Income taxes paid | $ 0 |
Shareholders Equity (Unaudited)
Shareholders Equity (Unaudited) - 3 months ended Jul. 31, 2017 - USD ($) | Common Stock | Receivable from Affiliate | Retained Earnings | Total |
Beginning Balance at Apr. 30, 2017 | $ (19,699) | $ 944,431 | $ 1,585,720 | |
Common Stock Outstanding at Apr. 30, 2017 | 14,935,511 | 14,935,511 | ||
Common Stock Value at Jul. 31, 2017 | $ 660,988 | |||
Net Income | (7,160) | $ (7,160) | ||
Ending Balance at Jul. 31, 2017 | $ (19,699) | $ 937,271 | $ 1,578,560 |
Company Organization and Descri
Company Organization and Description | 3 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Company Organization and Description | In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of normal recurring adjustments which are necessary for a fair presentation of the financial position and results of operations for the periods presented. The unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America. These condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s April 30, 2017 Annual Report on Form 10-K. The results of operations for the three months ended July 31, 2017 are not necessarily indicative of the operating results for the full year. Biosynergy, Inc. (the Company) was incorporated under the laws of the State of Illinois on February 9, 1976. It is primarily engaged in the development and marketing of medical, consumer and industrial thermometric and thermographic products that utilize cholesteric liquid crystals. The Company’s primary product, the HemoTemp II Blood Monitoring Device, accounted for approximately 91.02% of the sales during the quarter ending July 31, 2017 and 90.16% during the quarter ending July 31, 2016. The products are sold to hospitals, clinical end-users, laboratories and product dealers located throughout the United States. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Summary of Significant Accounting Policies | Cash The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. Inventories Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method. Depreciation Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $2,579 and $2,099 for the three month periods ending July 31, 2017 and 2016, respectively. Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year. Revenue Recognition The Company recognizes net sales revenue upon the shipment of product to customers. Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and once obtained, amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2017 was $2,171 and 2016 was $2,171. Patents relate to products that have been developed and by the Company. Patents pending relate to products under development. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. When dilutive, stock options are included as share equivalents using the treasury stock method in the calculation of diluted earnings per share. The Company has no outstanding options or other rights to acquire its unissued common shares. Comprehensive Income Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three month periods ending July 31, 2017 and 2016, there were no differences between the Company’s net income and comprehensive income. Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company implemented ASU 2015-17 during the quarter ended July 31, 2017 and have classified their deferred tax liability as non-current. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The (benefit) provision for income taxes consists of the following components for the three month periods ended July 31: 2017 2016 Current Federal $ (2,460 ) $ (4,117 ) State (808 ) (1,357 ) Provision (Benefit) for Income Taxes $ (3,268 ) $ (5,474 ) The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2017 2016 U.S. federal statutory tax rate 34.0 % 34.0 % State income tax expense, net of 5.0 5.0 Adjustment for prior year estimates — — Effect of graduated federal tax rates (7.66 ) (7.75 ) Effective Tax Rate 31.34 % 31.25 % Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Except for the ASUs listed below, those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. The amendments are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. At inception, a lessee must classify all leases as either finance or operating. The Company intends to adopt Topic 842 upon extension of the current lease for its facilities in Elk Grove Village or upon entering into a new lease agreement for alternative facilities on or about May 1, 2018. The Company is investigating the effect of adoption of Topic 842 on its results of operations and financial condition. However, it is not anticipated that adoption of Topic 842 will have a material impact on the results of operations or financial condition of the Company. In May 2014, the Financial Accounting Standard Board (FASB) issued ASU 2014-09, Revenue from Contract with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2015-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2015-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard as of May 1, 2018. |
Inventories
Inventories | 3 Months Ended |
Jul. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Inventories | Components of inventories are as follows: July 31, 2017 April 30, 2017 Raw materials $ 117,189 $ 142,713 Work-in-process 19,887 16,752 Finished goods 18,395 26,847 $ 155,471 $ 186,312 |
Common Stock
Common Stock | 3 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Common Stock | The Company’s common stock is traded in the over-the-counter market. However, there is no established public trading market due to limited and sporadic trades. The Company’s common stock is not listed on a recognized market or stock exchange. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Jul. 31, 2017 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | The Company and its affiliates are related through common stock ownership as follows as of July 31, 2017: Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0 % — % 100.0 % Fred K. Suzuki, Officer 4.1 30.0 — Lauane C. Addis, Officer — — — Jeanne S. Addis, Trustee — 28.1 — Mary K. Friske, Officer .3 .7 — Laurence C. Mead, Officer .4 10.0 — Beverly R. Suzuki 2.7 — — As of July 31, 2017, $19,699 was due from F. K. Suzuki International, Inc. These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account since April 30, 2006. A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $13,485 and $9,665 for the three months ended July 31, 2017 and 2016 respectively. |
Lease Commitments
Lease Commitments | 3 Months Ended |
Jul. 31, 2017 | |
Leases [Abstract] | |
Lease Commitments | In January 2015, the Company entered into a three-year lease agreement for its current facilities, which expires on April 30, 2018. The base rent under the lease escalates over the life of the lease. However, rent expense is recorded on a straight-line basis as required by accounting principles generally accepted in the United States of America. As of July 31, 2017, the Company’s approximate total future minimum lease payments are as follows: Year Ending April 30: 2018 66,956 Also included in the lease agreement are escalation clauses for the lessor’s increases in property taxes and other operating expenses. |
Customer Concentration
Customer Concentration | 3 Months Ended |
Jul. 31, 2017 | |
Accounting Policies [Abstract] | |
Customer Concentration | Shipments to one customer amounted to 28.65% of sales during the first three months of Fiscal 2018 compared to 29.42% during the comparative Fiscal 2017 period. As of July 31, 2017, there were outstanding accounts receivable from this customer of $59,526 compared to $56,432 at July 31, 2016. Shipments to another customer amounted to 33.85% of sales during the first three months of Fiscal 2018 and 29.17% of sales during the first three months of Fiscal 2017. As of July 31, 2017, there were outstanding accounts receivable from this customer of $109,008 compared to $35,497 at July 31, 2016. The Company had export sales of $8,650 during the first three months of Fiscal 2018, and export sales of $20,460 during the first three months of Fiscal 2017. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales and such sales are not considered to be material. |
Summary of Significant Accoun14
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Cash | The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. |
Receivables | Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. |
Inventories | Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method. |
Depreciation | Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $2,579 and $2,099 for the three month periods ending July 31, 2017 and 2016, respectively. |
Prepaid Expenses | Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year. |
Revenue Recognition | The Company recognizes net sales revenue upon the shipment of product to customers. |
Research and Development and Patents | Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and once obtained, amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2017 was $2,171 and 2016 was $2,171. Patents relate to products that have been developed and by the Company. Patents pending relate to products under development. |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Income Per Comon Share | Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. When dilutive, stock options are included as share equivalents using the treasury stock method in the calculation of diluted earnings per share. The Company has no outstanding options or other rights to acquire its unissued common shares. |
Comprehensive Income | Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three month periods ending July 31, 2017 and 2016, there were no differences between the Company’s net income and comprehensive income. |
Income Taxes | Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company implemented ASU 2015-17 during the quarter ended July 31, 2017 on a retrospective basis, and have classified their deferred tax liabilities as non-current. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The (benefit) provision for income taxes consists of the following components for the three month periods ended July 31: 2017 2016 Current Federal $ (2,460 ) $ (4,117 ) State (808 ) (1,357 ) Provision (Benefit) for Income Taxes $ (3,268 ) $ (5,474 ) The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2017 2016 U.S. federal statutory tax rate 34.0 % 34.0 % State income tax expense, net of 5.0 5.0 Adjustment for prior year estimates — — Effect of graduated federal tax rates (7.66 ) (7.75 ) Effective Tax Rate 31.34 % 31.25 % |
Recent Accounting Pronouncements | The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Except for the ASUs listed below, those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. The amendments are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. At inception, a lessee must classify all leases as either finance or operating. The Company intends to adopt Topic 842 upon extension of the current lease for its facilities in Elk Grove Village or upon entering into a new lease agreement for alternative facilities on or about May 1, 2018. The Company is investigating the effect of adoption of Topic 842 on its results of operations and financial condition. However, it is not anticipated that adoption of Topic 842 will have a material impact on the results of operations or financial condition of the Company. In May 2014, the Financial Accounting Standard Board (FASB) issued ASU 2014-09, Revenue from Contract with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2015-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2015-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard as of May 1, 2018. |
Summary of Significant Accoun15
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Provision (benefit) for Income Taxes | 2017 2016 Current Federal $ (2,460 ) $ (4,117 ) State (808 ) (1,357 ) Provision (Benefit) for Income Taxes $ (3,268 ) $ (5,474 ) |
Income Tax Rate | Period ended July 31, 2017 2016 U.S. federal statutory tax rate 34.0 % 34.0 % State income tax expense, net of 5.0 5.0 Adjustment for prior year estimates — — Effect of graduated federal tax rates (7.66 ) (7.75 ) Effective Tax Rate 31.34 % 31.25 % |
Depreciation
Depreciation | 3 Months Ended |
Jul. 31, 2017 | |
Accounting Policies [Abstract] | |
Depreciation (Details) | Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years. Depreciation expense was $2,579 and $2,099 for the three month periods ending July 31, 2017 and 2016, respectively. |
Research and Development and Pa
Research and Development and Patents | 3 Months Ended |
Jul. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Disclosure - Research and Development and Patents | Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and once obtained, amortized over the life of the respective patent on the straight-line method. Patent amortization expense for the three months ended July 31, 2017 was $2,171 and 2016 was $2,171. Patents relate to products that have been developed and by the Company. Patents pending relate to products under development. |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Jul. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Inventories | July 31, 2017 April 30, 2017 Raw materials $ 117,189 $ 142,713 Work-in-process 19,887 16,752 Finished goods 18,395 26,847 $ 155,471 $ 186,312 |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 3 Months Ended |
Jul. 31, 2017 | |
Related Party Transactions [Abstract] | |
Stock of Affiliates | Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0 % — % 100.0 % Fred K. Suzuki, Officer 4.1 30.0 — Lauane C. Addis, Officer — — — Jeanne S. Addis, Trustee — 28.1 — Mary K. Friske, Officer .3 .7 — Laurence C. Mead, Officer .4 10.0 — Beverly R. Suzuki 2.7 — — |
Summary of Significant Accoun20
Summary of Significant Accounting Policies (Tables) - Income Tax Rate (Details) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Notes to Financial Statements | ||
U.S. federal statutory tax rate | 34.00% | 34.00% |
State income tax expense, net of Federal tax benefit | 5.00% | 5.00% |
Adjustment for prior year estimates | 0.00% | 0.00% |
Effect of graduated federal tax rates | (7.66%) | (7.75%) |
Effective Tax Rate | 31.34% | 31.25% |
Summary of Significant Accoun21
Summary of Significant Accounting Policies (Tables) - Provision for Income Taxes (Details) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Current | ||
Federal | $ (2,460) | $ (4,117) |
State | (808) | (1,357) |
(Provision) benefit for Income Taxes | $ (3,268) | $ (5,474) |
Depreciation (Details Narrative
Depreciation (Details Narrative) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Accounting Policies [Abstract] | ||
Depreciation Expense | $ 2,579 | $ 2,099 |
Research and Development and 23
Research and Development and Patents (Details Narrative) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Patent amortization expense | $ 2,171 | $ 2,171 |
Inventories - Inventories (Deta
Inventories - Inventories (Details) - USD ($) | Jul. 31, 2017 | Apr. 30, 2017 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 117,189 | $ 142,713 |
Work-in-process | 19,887 | 16,752 |
Finished goods | 18,395 | 26,847 |
[us-gaap:InventoryGross] | $ 155,471 | $ 186,312 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 3 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Apr. 30, 2017 | |
Related Party Transactions [Abstract] | |||
Due from affiliate | $ 19,699 | $ 19,699 | |
Legal Fees | $ 13,485 | $ 9,665 |
Lease Commitments - Future Mini
Lease Commitments - Future Minimum Lease Expense (Details) - USD ($) | 12 Months Ended | |
Apr. 30, 2018 | Apr. 30, 2017 | |
Leases [Abstract] | ||
Future Minimum Lease Expense | $ 66,956 | $ 65,006 |
Customer Concentrations (Detail
Customer Concentrations (Details) - USD ($) | 3 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
Exports | $ 8,650 | $ 20,460 |
Customer One | ||
Accounts Receivable | $ 59,526 | $ 56,432 |
Sales | 28.65% | 29.42% |
Customer Two | ||
Accounts Receivable | $ 35,497 | $ 109,008 |
Sales | 33.85% | 29.17% |